Clinical Trial Detail

NCT ID NCT03528408
Title Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Suthee Rapisuwon
Indications

ocular melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.